Solabia strengthens its position in the nutrition market with the acquisition of a majority stake in BioActor, a leader in the development and marketing of clinically-proven natural active ingredients used by leading dietary supplement brands.
Founded in 2011 and located on the Maastricht health campus, BioActor is an innovator in the development and commercialization of clinically evaluated polyphenols, extracted from edible plants and fruits and used by the world's leading dietary supplement brands. Thanks to an in-house clinical research team with direct access to a state-of-the-art clinical research facility and a genuine passion for innovation, BioActor's health ingredients are all first-rate, offering dietary supplement brands the opportunity to develop unique solutions for consumers worldwide. BioActor currently exports to over 20 countries worldwide, serving leading brands in the nutrition and dietary supplement sectors.
Solabia is already present in the nutrition segment thanks to original ingredients recognized for their health benefits, notably Algatech's active ingredients derived from microalgae. This strategic investment will enable Solabia to benefit from a wider range of ingredients and BioActor's expertise, strengthening the positioning of its nutrition division in this fast-growing market, as customers increasingly seek high-quality active ingredients combining naturalness and proof of efficacy. This new partnership will also enable BioActor to continue to focus on R&D and product development, as well as expanding its production capacity to meet the growing global demand for its products. BioActor will become a center of excellence for innovation and clinical research within Solabia's nutrition division, and the tie-up will enable both companies to benefit from the combined network and expertise, as well as gaining access to new marketing channels and a broader customer base.
Hans van der Saag, founder and CEO of BioActor, retains a minority stake and his role as CEO of BioActor.
Commenting on the acquisition, Jean-Baptiste Dellon, Solabia's Chief Executive Officer, said: " We are very impressed by BioActor's dynamic team and innovative drive, and we are delighted to welcome them to Solabia. BioActor's cutting-edge R&D, impressive clinical research capabilities, market-leading product portfolio and well-established customer base will enable us to strengthen our position in the nutrition and dietary supplement markets. We look forward to working with BioActor to strengthen the growth of the current product portfolio and accelerate the development of new ingredients. "
Hans van der Saag, founder and CEO of BioActor, commented: " We are delighted to announce the acquisition of BioActor by Solabia. This is an important milestone for the company and the people behind its success, and an important step towards achieving our mission of bringing unique, clinically evaluated health ingredients to consumers worldwide. I am also grateful for the hard work and dedication of our employees. Together with Solabia, we are ready to extend BioActor's growth story as part of a larger organization with an extensive global footprint, a shared commitment to innovation, research and development, and an unwavering focus on using the benefits of nutrition to improve health for all. "
